Instead, let's look at $MRK's 2 dose escalation trials, which had basically the same design as $BLU's p2. Based on these trials, the 50mg had a cough reduction of -41% or -56%, depending on which trial you look at. I believe investors are looking at this range for comparison. https://t.co/LvyHOmNzvd